{"DataElement":{"publicId":"8003099","version":"1","preferredName":"Cancer Stage Reservation Assignment Name","preferredDefinition":"The reserved assignment for cancer and disease stage.","longName":"CA_RESERV_ASSIGN","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"8003094","version":"1","preferredName":"Malignant Neoplasm Stage Reservation Assignment","preferredDefinition":"A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas._The extent of a cancer in the body._The act of keeping back or setting aside for some future occasion._An allotting or an appointment to a particular person or use, or for a particular time or object.","longName":"8003100v1.0:8003092v1.0","context":"Alliance","contextVersion":"1","ObjectClass":{"publicId":"8003100","version":"1","preferredName":"Malignant Neoplasm Stage","preferredDefinition":"A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.:The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"C9305:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5681732-C2BA-4940-E053-4EBD850A6FD8","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"8003092","version":"1","preferredName":"Reservation Assignment","preferredDefinition":"The act of keeping back or setting aside for some future occasion.:An allotting or an appointment to a particular person or use, or for a particular time or object.","longName":"C71729:C25426","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Reservation","conceptCode":"C71729","definition":"The act of keeping back or setting aside for some future occasion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assignment","conceptCode":"C25426","definition":"An allotting or an appointment to a particular person or use, or for a particular time or object.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D567DB5B-FFDB-7C29-E053-4EBD850A0897","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008528","version":"1","preferredName":"Protocol Administration","preferredDefinition":"the management of a research protocol and its case report forms.","longName":"PROT_ADM","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1ECAD41-A932-34B1-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D567DB5B-FFEC-7C29-E053-4EBD850A0897","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"TAYLORT","dateModified":"2022-02-24","changeDescription":"TL released; 2/24/22.; A212102/TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"8002865","version":"1","preferredName":"Malignant Neoplasm Stage Assignment Name","preferredDefinition":"A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas._The extent of a cancer in the body._An allotting or an appointment to a particular person or use, or for a particular time or object._The words or language units by which a thing is known","longName":"8002865v1.0","context":"Alliance","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Bladder Cancer AJCC v7 Stage 4","valueDescription":"Bladder Cancer AJCC v7 Stage 4","ValueMeaning":{"publicId":"8002878","version":"1","preferredName":"Bladder Cancer AJCC v7 Stage 4","longName":"8002878","preferredDefinition":"Stage IV includes: (T4b, N0, M0); (Any T, N1-3, M0); (Any T, Any N, M1). T4b: Tumor invades pelvic wall, abdominal wall. N0: No regional lymph node metastasis. N1: Single regional lymph node metastasis in the true pelvis (hypogastric, obturator, external iliac, or presacral lymph node). N2: Multiple regional lymph node metastases in the true pelvis (hypogastric, obturator, external iliac, or presacral lymph node metastasis). N3: Metastasis to the common iliac lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5670DC7-E0AF-7B1A-E053-4EBD850AF485","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D5670DC7-E0C8-7B1A-E053-4EBD850AF485","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Bladder Cancer AJCC v7 Stage 3","valueDescription":"Bladder Cancer AJCC v7 Stage 3","ValueMeaning":{"publicId":"8002879","version":"1","preferredName":"Bladder Cancer AJCC v7 Stage 3","longName":"8002879","preferredDefinition":"Stage III includes: (T3a, N0, M0); (T3b, N0, M0); (T4a, N0, M0). T3a: Tumor microscopically invades perivesical tissue. T3b: Tumor macroscopically invades perivesical tissue (extravesical mass). T4a: Tumor invades prostatic stroma, uterus, vagina. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5670DC7-E0D2-7B1A-E053-4EBD850AF485","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D5670DC7-E0EB-7B1A-E053-4EBD850AF485","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Bladder Cancer AJCC v7 Stage 2","valueDescription":"Bladder Cancer AJCC v7 Stage 2","ValueMeaning":{"publicId":"8002880","version":"1","preferredName":"Bladder Cancer AJCC v7 Stage 2","longName":"8002880","preferredDefinition":"Stage II includes: (T2a, N0, M0); (T2b, N0, M0). T2a: Tumor invades superficial muscle (inner half). T2b: Tumor invades deep muscle (outer half). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th Eds.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5670DC7-E0F5-7B1A-E053-4EBD850AF485","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D5670DC7-E10E-7B1A-E053-4EBD850AF485","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Bladder Cancer AJCC v7 Stage 1","valueDescription":"Bladder Cancer AJCC v7 Stage 1","ValueMeaning":{"publicId":"8002881","version":"1","preferredName":"Bladder Cancer AJCC v7 Stage 1","longName":"8002881","preferredDefinition":"Stage I includes: T1, N0, M0. T1: Tumor invades subepithelial connective tissue. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5670DC7-E118-7B1A-E053-4EBD850AF485","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D5670DC7-E131-7B1A-E053-4EBD850AF485","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Lung Cancer AJCC v7 Stage 4","valueDescription":"Lung Cancer AJCC v7 Stage 4","ValueMeaning":{"publicId":"8002882","version":"1","preferredName":"Lung Cancer AJCC v7 Stage 4","longName":"8002882","preferredDefinition":"Stage IV includes: (Any T, Any N, M1a); (Any T, Any N, M1b). M1a: Lung cancer with separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant pleural (or pericardial) effusion. M1b: Distant metastasis. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5662440-3FC4-3089-E053-4EBD850AE637","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D5662440-3FDD-3089-E053-4EBD850AE637","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Lung Cancer AJCC v7 Stage 3","valueDescription":"Lung Cancer AJCC v7 Stage 3","ValueMeaning":{"publicId":"8002883","version":"1","preferredName":"Lung Cancer AJCC v7 Stage 3","longName":"8002883","preferredDefinition":"Stage III includes: IIIA (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0) and IIIB (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0). T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe. N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes. N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes. M0: No distant metastasis. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5662440-3FE7-3089-E053-4EBD850AE637","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D5662440-4000-3089-E053-4EBD850AE637","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Lung Cancer AJCC v7 Stage 2","valueDescription":"Lung Cancer AJCC v7 Stage 2","ValueMeaning":{"publicId":"8002884","version":"1","preferredName":"Lung Cancer AJCC v7 Stage 2","longName":"8002884","preferredDefinition":"Stage II includes: IIA (T2b, N0, M0); (T1a, N1, M0); (T1b, N1, M0); (T2a, N1, M0) and IIB (T2b, N1, M0); (T3, N0, M0). T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension. T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a. T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension. T3: Lung cancer with a tumor size more than 7 cm or one that directly invades any of the following: parietal pleural (PL3) chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus (less than 2 cm distal to the carina but without involvement of the carina); or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe. N0: No regional lymph node metastasis. N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5662440-400A-3089-E053-4EBD850AE637","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D5662440-4023-3089-E053-4EBD850AE637","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Lung Cancer AJCC v7 Stage 1","valueDescription":"Lung Cancer AJCC v7 Stage 1","ValueMeaning":{"publicId":"8002885","version":"1","preferredName":"Lung Cancer AJCC v7 Stage 1","longName":"8002885","preferredDefinition":"Stage I includes: IA: (T1a, N0, M0); (T1b, N0, M0) and IB: (T2a, N0, M0). T1a: Lung cancer with a tumor size of 2 cm or less n greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a. T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension. N0: No regional lymph metastasis. M0: No distant metastasis. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5662440-402D-3089-E053-4EBD850AE637","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D5662440-4046-3089-E053-4EBD850AE637","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Hepatobiliary Cancer AJCC v7 Stage 4","valueDescription":"Hepatobiliary Cancer AJCC v7 Stage 4","ValueMeaning":{"publicId":"8002886","version":"1","preferredName":"Hepatobiliary Cancer AJCC v7 Stage 4","longName":"8002886","preferredDefinition":"Hepatobiliary Cancer AJCC v7 Stage 4","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5662440-4050-3089-E053-4EBD850AE637","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D5662440-4069-3089-E053-4EBD850AE637","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Hepatobiliary Cancer AJCC v7 Stage 3","valueDescription":"Hepatobiliary Cancer AJCC v7 Stage 3","ValueMeaning":{"publicId":"8002887","version":"1","preferredName":"Hepatobiliary Cancer AJCC v7 Stage 3","longName":"8002887","preferredDefinition":"Hepatobiliary Cancer AJCC v7 Stage 3","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5662440-4073-3089-E053-4EBD850AE637","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D5662440-408C-3089-E053-4EBD850AE637","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Hepatobiliary Cancer AJCC v7 Stage 2","valueDescription":"Hepatobiliary Cancer AJCC v7 Stage 2","ValueMeaning":{"publicId":"8002888","version":"1","preferredName":"Hepatobiliary Cancer AJCC v7 Stage 2","longName":"8002888","preferredDefinition":"Hepatobiliary Cancer AJCC v7 Stage 2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5662440-4096-3089-E053-4EBD850AE637","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D5662440-40AF-3089-E053-4EBD850AE637","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Hepatobiliary Cancer AJCC v7 Stage 1","valueDescription":"Hepatobiliary Cancer AJCC v7 Stage 1","ValueMeaning":{"publicId":"8002889","version":"1","preferredName":"Hepatobiliary Cancer AJCC v7 Stage 1","longName":"8002889","preferredDefinition":"Hepatobiliary Cancer AJCC v7 Stage 1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5662440-40B9-3089-E053-4EBD850AE637","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D5662440-40D2-3089-E053-4EBD850AE637","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Head and Neck Cancer AJCC v7 Stage 4","valueDescription":"Head and Neck Cancer AJCC v7 Stage 4","ValueMeaning":{"publicId":"8002890","version":"1","preferredName":"Head and Neck Cancer AJCC v7 Stage 4","longName":"8002890","preferredDefinition":"Head and Neck Cancer AJCC v7 Stage 4","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5662440-40DC-3089-E053-4EBD850AE637","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D5662440-40F5-3089-E053-4EBD850AE637","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Head and Neck Cancer AJCC v7 Stage 3","valueDescription":"Head and Neck Cancer AJCC v7 Stage 3","ValueMeaning":{"publicId":"8002891","version":"1","preferredName":"Head and Neck Cancer AJCC v7 Stage 3","longName":"8002891","preferredDefinition":"Head and Neck Cancer AJCC v7 Stage 3","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5662440-40FF-3089-E053-4EBD850AE637","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D5662440-4118-3089-E053-4EBD850AE637","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Head and Neck Cancer AJCC v7 Stage 2","valueDescription":"Head and Neck Cancer AJCC v7 Stage 2","ValueMeaning":{"publicId":"8002892","version":"1","preferredName":"Head and Neck Cancer AJCC v7 Stage 2","longName":"8002892","preferredDefinition":"Head and Neck Cancer AJCC v7 Stage 2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5662440-4122-3089-E053-4EBD850AE637","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D5662440-413B-3089-E053-4EBD850AE637","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Head and Neck Cancer AJCC v7 Stage 1","valueDescription":"Head and Neck Cancer AJCC v7 Stage 1","ValueMeaning":{"publicId":"8002893","version":"1","preferredName":"Head and Neck Cancer AJCC v7 Stage 1","longName":"8002893","preferredDefinition":"Head and Neck Cancer AJCC v7 Stage 1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5662440-4145-3089-E053-4EBD850AE637","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D5662440-415E-3089-E053-4EBD850AE637","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Ovary Cancer AJCC v7 Stage 4","valueDescription":"Ovary Cancer AJCC v7 Stage 4","ValueMeaning":{"publicId":"8003040","version":"1","preferredName":"Ovary Cancer AJCC v7 Stage 4","longName":"8003040","preferredDefinition":"Stage IV includes: Any T, Any N, M1. M1: Distant metastasis (excludes peritoneal metastasis). (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D56636C2-70D8-273F-E053-4EBD850ADDCD","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D56636C2-70F1-273F-E053-4EBD850ADDCD","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Ovary Cancer AJCC v7 Stage 3","valueDescription":"Ovary Cancer AJCC v7 Stage 3","ValueMeaning":{"publicId":"8003041","version":"1","preferredName":"Ovary Cancer AJCC v7 Stage 3","longName":"8003041","preferredDefinition":"Stage III includes: T3, N0, M0. T3: Tumor involves one or both ovaries with microscopically confirmed peritoneal metastasis outside pelvis. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D56636C2-70FB-273F-E053-4EBD850ADDCD","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D56636C2-7114-273F-E053-4EBD850ADDCD","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Ovary Cancer AJCC v7 Stage 2","valueDescription":"Ovary Cancer AJCC v7 Stage 2","ValueMeaning":{"publicId":"8003042","version":"1","preferredName":"Ovary Cancer AJCC v7 Stage 2","longName":"8003042","preferredDefinition":"Stage II includes: T2, N0, M0. T2: Tumor involves one or both ovaries with pelvic extension and/or implants. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D56636C2-711E-273F-E053-4EBD850ADDCD","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D56636C2-7137-273F-E053-4EBD850ADDCD","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Ovary Cancer AJCC v7 Stage 1","valueDescription":"Ovary Cancer AJCC v7 Stage 1","ValueMeaning":{"publicId":"8003043","version":"1","preferredName":"Ovary Cancer AJCC v7 Stage 1","longName":"8003043","preferredDefinition":"Stage I includes: T1, N0, M0. T1: Tumor limited to ovaries (one or both). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D56636C2-7141-273F-E053-4EBD850ADDCD","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D56636C2-715A-273F-E053-4EBD850ADDCD","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Leukemia AML","valueDescription":"Leukemia AML","ValueMeaning":{"publicId":"8003044","version":"1","preferredName":"Leukemia AML","longName":"8003044","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D56636C2-7164-273F-E053-4EBD850ADDCD","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D56636C2-717D-273F-E053-4EBD850ADDCD","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Leukemia ALL","valueDescription":"Leukemia ALL","ValueMeaning":{"publicId":"8003045","version":"1","preferredName":"Leukemia ALL","longName":"8003045","preferredDefinition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D56636C2-7187-273F-E053-4EBD850ADDCD","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D56636C2-71A0-273F-E053-4EBD850ADDCD","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Leukemia CML","valueDescription":"Leukemia CML","ValueMeaning":{"publicId":"8003046","version":"1","preferredName":"Leukemia CML","longName":"8003046","preferredDefinition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D56636C2-71AA-273F-E053-4EBD850ADDCD","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D56636C2-71C3-273F-E053-4EBD850ADDCD","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Leukemia CLL","valueDescription":"Leukemia CLL","ValueMeaning":{"publicId":"8003047","version":"1","preferredName":"Leukemia CLL","longName":"8003047","preferredDefinition":"The most common type of chronic lymphoid leukemia. It comprises 90% of chronic lymphoid leukemias in the United States. Morphologically, the neoplastic cells are small, round B-lymphocytes. This type of leukemia is not considered to be curable with available therapy. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D56636C2-71CD-273F-E053-4EBD850ADDCD","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D56636C2-71E6-273F-E053-4EBD850ADDCD","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Lymphoma Ann Arbor Stage 4","valueDescription":"Lymphoma Ann Arbor Stage 4","ValueMeaning":{"publicId":"8003048","version":"1","preferredName":"Lymphoma Ann Arbor Stage 4","longName":"8003048","preferredDefinition":"Ann Arbor Classification: Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s); or any involvement of the liver or bone marrow, lungs (other than by direct extension from another site), or cerebrospinal fluid.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D56636C2-71F0-273F-E053-4EBD850ADDCD","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D56636C2-7209-273F-E053-4EBD850ADDCD","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Breast Cancer AJCC v7 Stage 4","valueDescription":"Breast Cancer AJCC v7 Stage 4","ValueMeaning":{"publicId":"8003052","version":"1","preferredName":"Breast Cancer AJCC v7 Stage 4","longName":"8003052","preferredDefinition":"Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 6th and 7th Eds.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D56796C8-BDB4-0ACD-E053-4EBD850AE6E9","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D56796C8-BDCD-0ACD-E053-4EBD850AE6E9","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Breast Cancer AJCC v7 Stage 3","valueDescription":"Breast Cancer AJCC v7 Stage 3","ValueMeaning":{"publicId":"8003053","version":"1","preferredName":"Breast Cancer AJCC v7 Stage 3","longName":"8003053","preferredDefinition":"Stage III includes: IIIA : (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0), IIIB: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0), and IIIC: (any T, N3, M0). T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules). N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases. N3: Metastases in ipsilateral infraclavicular (level III) axillary lymph nodes(s) with or without level I, II axillary lymph node involvement; or in clinically detected ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+). (AJCC 7th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D56796C8-BDD7-0ACD-E053-4EBD850AE6E9","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D56796C8-BDF0-0ACD-E053-4EBD850AE6E9","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Breast Cancer AJCC v7 Stage 2","valueDescription":"Breast Cancer AJCC v7 Stage 2","ValueMeaning":{"publicId":"8003054","version":"1","preferredName":"Breast Cancer AJCC v7 Stage 2","longName":"8003054","preferredDefinition":"Stage II includes: IIA: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0) and IIB: (T2, N1, M0); (T3, N0, M0). T0: No evidence of primary tumor. T1: Tumor 2.0 cm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 2.0 cm but not more than 5.0 cm in greatest dimension. T3: Tumor more than 5.0 cm in greatest dimension. N1: Metastasis to movable ipsilateral axillary lymph node(s). M0: No distant metastasis. (AJCC 6th and 7th Eds.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D56796C8-BDFA-0ACD-E053-4EBD850AE6E9","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D56796C8-BE13-0ACD-E053-4EBD850AE6E9","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Breast Cancer AJCC v7 Stage 1","valueDescription":"Breast Cancer AJCC v7 Stage 1","ValueMeaning":{"publicId":"8003055","version":"1","preferredName":"Breast Cancer AJCC v7 Stage 1","longName":"8003055","preferredDefinition":"Stage I includes: IA: T1, N0, M0 and IB: (T0, N1mi, M0); (T1, N1mi, M0). T1: Tumor 20 mm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T0: No evidence of primary tumor. N0: No regional lymph node metastasis. N1mi: Nodal micrometastases. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+). (AJCC 7th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D56796C8-BE1D-0ACD-E053-4EBD850AE6E9","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D56796C8-BE36-0ACD-E053-4EBD850AE6E9","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Esophageal or Gastroesophageal  Cancer AJCC v7 Stage 4","valueDescription":"Esophageal or Gastroesophageal  Cancer AJCC v7 Stage 4","ValueMeaning":{"publicId":"8003056","version":"1","preferredName":"Esophageal or Gastroesophageal  Cancer AJCC v7 Stage 4","longName":"8003056","preferredDefinition":"Esophageal or Gastroesophageal  Cancer AJCC v7 Stage 4","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D56796C8-BE40-0ACD-E053-4EBD850AE6E9","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D56796C8-BE59-0ACD-E053-4EBD850AE6E9","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Esophageal or Gastroesophageal Cancer AJCC v7 Stage 3","valueDescription":"Esophageal or Gastroesophageal Cancer AJCC v7 Stage 3","ValueMeaning":{"publicId":"8003057","version":"1","preferredName":"Esophageal or Gastroesophageal Cancer AJCC v7 Stage 3","longName":"8003057","preferredDefinition":"Esophageal or Gastroesophageal Cancer AJCC v7 Stage 3","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D56796C8-BE63-0ACD-E053-4EBD850AE6E9","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D56796C8-BE7C-0ACD-E053-4EBD850AE6E9","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Esophageal or Gastroesophageal Cancer AJCC v7 Stage 2","valueDescription":"Esophageal or Gastroesophageal Cancer AJCC v7 Stage 2","ValueMeaning":{"publicId":"8003058","version":"1","preferredName":"Esophageal or Gastroesophageal Cancer AJCC v7 Stage 2","longName":"8003058","preferredDefinition":"Esophageal or Gastroesophageal Cancer AJCC v7 Stage 2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D56796C8-BE86-0ACD-E053-4EBD850AE6E9","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D56796C8-BE9F-0ACD-E053-4EBD850AE6E9","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Esophageal or Gastroesophageal Cancer AJCC v7 Stage 1","valueDescription":"Esophageal or Gastroesophageal Cancer AJCC v7 Stage 1","ValueMeaning":{"publicId":"8003059","version":"1","preferredName":"Esophageal or Gastroesophageal Cancer AJCC v7 Stage 1","longName":"8003059","preferredDefinition":"Esophageal or Gastroesophageal Cancer AJCC v7 Stage 1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D56796C8-BEA9-0ACD-E053-4EBD850AE6E9","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D56796C8-BEC2-0ACD-E053-4EBD850AE6E9","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Multiple Myeloma Revised International Staging System Stage 3","valueDescription":"Multiple Myeloma Revised International Staging System Stage 3","ValueMeaning":{"publicId":"8003061","version":"1","preferredName":"Multiple Myeloma Revised International Staging System Stage 3","longName":"8003061","preferredDefinition":"Serum beta-2-microglobulin 5.5 mg/L or more and high-risk cytogenetics and/or high LDH. High risk cytogenetics consist of one or more of the following: del17p, t(4;14), or t(14;16). (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D56796C8-BEEF-0ACD-E053-4EBD850AE6E9","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D56796C8-BF08-0ACD-E053-4EBD850AE6E9","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Multiple Myeloma Revised International Staging System Stage 2","valueDescription":"Multiple Myeloma Revised International Staging System Stage 2","ValueMeaning":{"publicId":"8003062","version":"1","preferredName":"Multiple Myeloma Revised International Staging System Stage 2","longName":"8003062","preferredDefinition":"Not stage I or III. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D56796C8-BF12-0ACD-E053-4EBD850AE6E9","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D56796C8-BF2B-0ACD-E053-4EBD850AE6E9","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Multiple Myeloma Revised International Staging System Stage 1","valueDescription":"Multiple Myeloma Revised International Staging System Stage 1","ValueMeaning":{"publicId":"8003063","version":"1","preferredName":"Multiple Myeloma Revised International Staging System Stage 1","longName":"8003063","preferredDefinition":"Serum beta-2-microglobulin less than 3.5 mg/L and serum albumin 3.5 g/dL or more and no high-risk cytogenetics and normal LDH. High risk cytogenetics consist of one or more of the following: del17p, t(4;14), or t(14;16). (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D56796C8-BF35-0ACD-E053-4EBD850AE6E9","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D56796C8-BF4E-0ACD-E053-4EBD850AE6E9","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Pancreas Cancer AJCC v7 Stage 4","valueDescription":"Pancreas Cancer AJCC v7 Stage 4","ValueMeaning":{"publicId":"8003064","version":"1","preferredName":"Pancreas Cancer AJCC v7 Stage 4","longName":"8003064","preferredDefinition":"Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 6th and 7th Eds.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D56796C8-BF58-0ACD-E053-4EBD850AE6E9","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D56796C8-BF71-0ACD-E053-4EBD850AE6E9","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Pancreas Cancer AJCC v7 Stage 3","valueDescription":"Pancreas Cancer AJCC v7 Stage 3","ValueMeaning":{"publicId":"8003065","version":"1","preferredName":"Pancreas Cancer AJCC v7 Stage 3","longName":"8003065","preferredDefinition":"Stage III includes: T4, Any N, M0. T4: Tumor involves the celiac axis or the superior mesenteric artery. M0: No distant metastasis. (AJCC 6th and 7th Eds.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D56796C8-BF7B-0ACD-E053-4EBD850AE6E9","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D56796C8-BF94-0ACD-E053-4EBD850AE6E9","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Pancreas Cancer AJCC v7 Stage 2","valueDescription":"Pancreas Cancer AJCC v7 Stage 2","ValueMeaning":{"publicId":"8003066","version":"1","preferredName":"Pancreas Cancer AJCC v7 Stage 2","longName":"8003066","preferredDefinition":"Stage II includes: IIA (T3, N0, M0); IIB (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T1: Tumor limited to the pancreas 2 cm or less in greatest dimension. T2: Tumor limited to the pancreas, more than 2 cm in greatest dimension. T3: Tumor extends beyond the pancreas but without involvement of the celiac axis or the superior mesenteric artery. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th Eds.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D56796C8-BF9E-0ACD-E053-4EBD850AE6E9","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D56796C8-BFB7-0ACD-E053-4EBD850AE6E9","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Pancreas Cancer AJCC v7 Stage 1","valueDescription":"Pancreas Cancer AJCC v7 Stage 1","ValueMeaning":{"publicId":"8003067","version":"1","preferredName":"Pancreas Cancer AJCC v7 Stage 1","longName":"8003067","preferredDefinition":"Stage I includes: IA (T1, N0, M0); IB (T2, N0, M0). T1: Tumor limited to the pancreas 2 cm or less in greatest dimension. T2: Tumor limited to the pancreas, more than 2 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th Eds.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D56796C8-BFC1-0ACD-E053-4EBD850AE6E9","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D56796C8-BFDA-0ACD-E053-4EBD850AE6E9","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Lymphoma Ann Arbor Stage 3","valueDescription":"Lymphoma Ann Arbor Stage 3","ValueMeaning":{"publicId":"8003049","version":"1","preferredName":"Lymphoma Ann Arbor Stage 3","longName":"8003049","preferredDefinition":"Ann Arbor Classification: Stage III: Involvement of lymph node regions on both sides of the diaphragm (III), which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE,S).","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D56636C2-7213-273F-E053-4EBD850ADDCD","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D56636C2-722C-273F-E053-4EBD850ADDCD","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Lymphoma Ann Arbor Stage 2","valueDescription":"Lymphoma Ann Arbor Stage 2","ValueMeaning":{"publicId":"8003050","version":"1","preferredName":"Lymphoma Ann Arbor Stage 2","longName":"8003050","preferredDefinition":"Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE).","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D56636C2-7236-273F-E053-4EBD850ADDCD","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D56636C2-724F-273F-E053-4EBD850ADDCD","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Lymphoma Ann Arbor Stage 1","valueDescription":"Lymphoma Ann Arbor Stage 1","ValueMeaning":{"publicId":"8003051","version":"1","preferredName":"Lymphoma Ann Arbor Stage 1","longName":"8003051","preferredDefinition":"Ann Arbor Classification: Stage I: Involvement of a single lymph node region (I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE) (rare in Hodgkin lymphoma).","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D56636C2-7259-273F-E053-4EBD850ADDCD","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D56636C2-7272-273F-E053-4EBD850ADDCD","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Sarcoma Cancer AJCC v7 Stage 4","valueDescription":"Sarcoma Cancer AJCC v7 Stage 4","ValueMeaning":{"publicId":"8003068","version":"1","preferredName":"Sarcoma Cancer AJCC v7 Stage 4","longName":"8003068","preferredDefinition":"Sarcoma Cancer AJCC v7 Stage 4","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D567C84B-4141-4E92-E053-4EBD850A2849","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D567C84B-415A-4E92-E053-4EBD850A2849","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Sarcoma Cancer AJCC v7 Stage 3","valueDescription":"Sarcoma Cancer AJCC v7 Stage 3","ValueMeaning":{"publicId":"8003069","version":"1","preferredName":"Sarcoma Cancer AJCC v7 Stage 3","longName":"8003069","preferredDefinition":"Sarcoma Cancer AJCC v7 Stage 3","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D567C84B-4164-4E92-E053-4EBD850A2849","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D567C84B-417D-4E92-E053-4EBD850A2849","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Sarcoma Cancer AJCC v7 Stage 2","valueDescription":"Sarcoma Cancer AJCC v7 Stage 2","ValueMeaning":{"publicId":"8003070","version":"1","preferredName":"Sarcoma Cancer AJCC v7 Stage 2","longName":"8003070","preferredDefinition":"Sarcoma Cancer AJCC v7 Stage 2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D567C84B-4187-4E92-E053-4EBD850A2849","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D567C84B-41A0-4E92-E053-4EBD850A2849","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Sarcoma Cancer AJCC v7 Stage 1","valueDescription":"Sarcoma Cancer AJCC v7 Stage 1","ValueMeaning":{"publicId":"8003071","version":"1","preferredName":"Sarcoma Cancer AJCC v7 Stage 1","longName":"8003071","preferredDefinition":"Sarcoma Cancer AJCC v7 Stage 1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D567C84B-41AA-4E92-E053-4EBD850A2849","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D567C84B-41C3-4E92-E053-4EBD850A2849","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Melanoma Cancer AJCC v7 Stage 4","valueDescription":"Melanoma Cancer AJCC v7 Stage 4","ValueMeaning":{"publicId":"8003072","version":"1","preferredName":"Melanoma Cancer AJCC v7 Stage 4","longName":"8003072","preferredDefinition":"Stage IV includes: (Any T, Any N, M1). M1: Distant metastasis. (from AJCC 6th and 7th Eds.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D567C84B-41CD-4E92-E053-4EBD850A2849","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D567C84B-41E6-4E92-E053-4EBD850A2849","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Melanoma Cancer AJCC v7 Stage 3","valueDescription":"Melanoma Cancer AJCC v7 Stage 3","ValueMeaning":{"publicId":"8003073","version":"1","preferredName":"Melanoma Cancer AJCC v7 Stage 3","longName":"8003073","preferredDefinition":"Stage III includes: Any T, N1-3, M0. Stage III is divided into three pathologic subgroups: IIIA, IIIB, and IIIC. There are no clinical subgroups for stage III. N1: Cutaneous melanoma with metastasis in one regional lymph node. N2: Cutaneous melanoma with metastases in 2-3 regional lymph nodes or in transit met(s)/satellite(s) without metastatic nodes. N3: Cutaneous melanoma with 4 or more metastatic nodes, or matted nodes, or in transit met(s)/satellite(s) with metastatic node(s). M0: No detectable evidence of distant metastases. (from AJCC 7th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D567C84B-41F0-4E92-E053-4EBD850A2849","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D567C84B-4209-4E92-E053-4EBD850A2849","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Melanoma Cancer AJCC v7 Stage 2","valueDescription":"Melanoma Cancer AJCC v7 Stage 2","ValueMeaning":{"publicId":"8003074","version":"1","preferredName":"Melanoma Cancer AJCC v7 Stage 2","longName":"8003074","preferredDefinition":"Stage II includes: IIA: (T2b, N0, M0); (T3a, N0, M0); IIB: (T3b, N0, M0); (T4a, N0, M0); IIC: (T4b, N0, M0). T2b: Cutaneous melanoma with a tumor measuring 1.01-2.0 mm in thickness, with ulceration. T3a: Cutaneous melanoma with a tumor measuring 2.01-4.0 mm in thickness, without ulceration. T3b: Cutaneous melanoma with a tumor measuring 2.01-4.0 mm in thickness, with ulceration. T4a: Cutaneous melanoma with a tumor measuring more than 4.0 mm in thickness, without ulceration. T4b: Cutaneous melanoma with a tumor measuring more than 4.0 mm in thickness, with ulceration. N0: No regional lymph node metastases. M0: No detectable evidence of distant metastases. (from AJCC 6th and 7th Eds.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D567C84B-4213-4E92-E053-4EBD850A2849","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D567C84B-422C-4E92-E053-4EBD850A2849","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Melanoma Cancer AJCC v7 Stage 1","valueDescription":"Melanoma Cancer AJCC v7 Stage 1","ValueMeaning":{"publicId":"8003075","version":"1","preferredName":"Melanoma Cancer AJCC v7 Stage 1","longName":"8003075","preferredDefinition":"Stage I includes: IA: (T1a, N0, M0); IB: (T1b, N0, M0); (T2a, N0, M0). T1a: Cutaneous melanoma with a tumor measuring 1.0 mm or less in thickness, without ulceration and mitosis less than 1/mm2. T1b: Cutaneous melanoma with a tumor measuring 1.0 mm or less in thickness, with ulceration or mitoses equal to or more than 1/mm2. T2a: Cutaneous melanoma with a tumor measuring 1.01-2.0 mm in thickness, without ulceration. N0: No regional lymph node metastases. M0: No detectable evidence of distant metastases. (from AJCC 7th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D567C84B-4236-4E92-E053-4EBD850A2849","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D567C84B-424F-4E92-E053-4EBD850A2849","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Prostate Cancer AJCC v7 Stage 4","valueDescription":"Prostate Cancer AJCC v7 Stage 4","ValueMeaning":{"publicId":"8003076","version":"1","preferredName":"Prostate Cancer AJCC v7 Stage 4","longName":"8003076","preferredDefinition":"Stage IV includes: (T4, N0, M0, Any PSA, Any Gleason); (Any T, N1, M0, Any PSA, Any Gleason); (Any T, Any N, M1, Any PSA, Any Gleason). cT4: Tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall. pT4: Invasion of rectum, levator muscles, and/or pelvic wall. N1: Metastasis in regional lymph node(s). M1: Distant metastasis. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D567C84B-4259-4E92-E053-4EBD850A2849","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D567C84B-4272-4E92-E053-4EBD850A2849","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Prostate Cancer AJCC v7 Stage 3","valueDescription":"Prostate Cancer AJCC v7 Stage 3","ValueMeaning":{"publicId":"8003077","version":"1","preferredName":"Prostate Cancer AJCC v7 Stage 3","longName":"8003077","preferredDefinition":"Stage III includes: T3a-b, N0, M0, Any PSA, Any Gleason. cT3a: Tumor with extracapsular extension (unilateral or bilateral). pT3a: Tumor with extraprostatic extension or microscopic invasion of bladder neck. T3b: Tumor invades seminal vesicle(s). cN0: No regional lymph node metastasis. pN0: No positive regional nodes. M0: No distant metastasis. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D567C84B-427C-4E92-E053-4EBD850A2849","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D567C84B-4295-4E92-E053-4EBD850A2849","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Prostate Cancer AJCC v7 Stage 2","valueDescription":"Prostate Cancer AJCC v7 Stage 2","ValueMeaning":{"publicId":"8003078","version":"1","preferredName":"Prostate Cancer AJCC v7 Stage 2","longName":"8003078","preferredDefinition":"Stage II includes: IIA (T1a-c, N0, M0, PSA less than 20, Gleason 7); (T1a-c, N0, M0, PSA equal or more than 10 and less than 20, Gleason equal or less than 6); (T2a, N0, M0, PSA less than 20, Gleason equal or less than 7); (T2b, N0, M0, PSA less than 20, Gleason equal or less than 7); (T2b, N0, M0, PSA X, Gleason X); IIB (T2c, N0, M0, Any PSA, Any Gleason); (T1-2, N0, M0, PSA equal or more than 20, Any Gleason); (T1-2, N0, M0, Any PSA, Gleason equal or more than 8). T1a: Tumor incidental histologic finding in 5% or less of tissue resected. T1b: Tumor incidental histologic finding in more than 5% of tissue resected. T1c: Tumor identified by needle biopsy (e.g., because of elevated PSA). T2a: Tumor involves one-half of one lobe or less. T2b: Tumor involves more than one-half of one lobe, but not both lobes. T2c: Tumor involves both lobes. cN0: No regional lymph node metastasis. pN0: No positive regional nodes. M0: No distant metastasis. Gleason 7: Moderately differentiated (moderate anaplasia). Gleason Equal or Less than 6: Well differentiated (slight anaplasia). Gleason equal or more than 8: Poorly differentiated/undifferentiated (marked anaplasia). (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D567C84B-429F-4E92-E053-4EBD850A2849","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D567C84B-42B8-4E92-E053-4EBD850A2849","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Prostate Cancer AJCC v7 Stage 1","valueDescription":"Prostate Cancer AJCC v7 Stage 1","ValueMeaning":{"publicId":"8003079","version":"1","preferredName":"Prostate Cancer AJCC v7 Stage 1","longName":"8003079","preferredDefinition":"Stage I includes: (T1a-c, N0, M0, PSA less than 10, Gleason equal or less than 6); (T2a, N0, M0, PSA less than 10, Gleason equal or less than 6); (T1-2a, N0, M0, PSA X, Gleason X). T1a: Tumor incidental histologic finding in 5% or less of tissue resected. T1b: Tumor incidental histologic finding in more than 5% of tissue resected. T1c: Tumor identified by needle biopsy (e.g., because of elevated PSA). T2a: Tumor involves one-half of one lobe or less. cN0: No regional lymph node metastasis. pN0: No positive regional nodes. M0: No distant metastasis. Gleason Equal or Less than 6: Well differentiated (slight anaplasia). Gleason X: Gleason score cannot be processed. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D567C84B-42C2-4E92-E053-4EBD850A2849","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D567C84B-42DB-4E92-E053-4EBD850A2849","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Endometrium Cancer AJCC v7 Stage 4","valueDescription":"Endometrium Cancer AJCC v7 Stage 4","ValueMeaning":{"publicId":"8003080","version":"1","preferredName":"Endometrium Cancer AJCC v7 Stage 4","longName":"8003080","preferredDefinition":"Endometrium Cancer AJCC v7 Stage 4","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D567C84B-42E5-4E92-E053-4EBD850A2849","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D567C84B-42FE-4E92-E053-4EBD850A2849","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Endometrium Cancer AJCC v7 Stage 3","valueDescription":"Endometrium Cancer AJCC v7 Stage 3","ValueMeaning":{"publicId":"8003081","version":"1","preferredName":"Endometrium Cancer AJCC v7 Stage 3","longName":"8003081","preferredDefinition":"Endometrium Cancer AJCC v7 Stage 3","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D567C84B-4308-4E92-E053-4EBD850A2849","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D567C84B-4321-4E92-E053-4EBD850A2849","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Endometrium Cancer AJCC v7 Stage 2","valueDescription":"Endometrium Cancer AJCC v7 Stage 2","ValueMeaning":{"publicId":"8003082","version":"1","preferredName":"Endometrium Cancer AJCC v7 Stage 2","longName":"8003082","preferredDefinition":"Endometrium Cancer AJCC v7 Stage 2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D567C84B-432B-4E92-E053-4EBD850A2849","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D567C84B-4344-4E92-E053-4EBD850A2849","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Endometrium Cancer AJCC v7 Stage 1","valueDescription":"Endometrium Cancer AJCC v7 Stage 1","ValueMeaning":{"publicId":"8003083","version":"1","preferredName":"Endometrium Cancer AJCC v7 Stage 1","longName":"8003083","preferredDefinition":"Endometrium Cancer AJCC v7 Stage 1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D567C84B-434E-4E92-E053-4EBD850A2849","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D567C84B-4367-4E92-E053-4EBD850A2849","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Kidney Cancer AJCC v7 Stage 4","valueDescription":"Kidney Cancer AJCC v7 Stage 4","ValueMeaning":{"publicId":"8003084","version":"1","preferredName":"Kidney Cancer AJCC v7 Stage 4","longName":"8003084","preferredDefinition":"Stage IV includes: (T4, Any N, M0); (Any T, Any N, M1). T4: Tumor invades beyond Gerota's fascia (including contiguous extension into the ipsilateral adrenal gland). M0: No distant metastasis. M1: Distant metastasis. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D567C84B-4371-4E92-E053-4EBD850A2849","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D567C84B-438A-4E92-E053-4EBD850A2849","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Kidney Cancer AJCC v7 Stage 3","valueDescription":"Kidney Cancer AJCC v7 Stage 3","ValueMeaning":{"publicId":"8003085","version":"1","preferredName":"Kidney Cancer AJCC v7 Stage 3","longName":"8003085","preferredDefinition":"Stage III includes: (T1 or T2, N1, M0); (T3, N0 or N1, M0). T1: Lesions have been divided into T1a and T1b. T1a is defined as tumor 4 cm or less in greatest dimension, limited to the kidney. T1b is defined as tumor greater than 4 cm but not more than 7 cm in greatest dimension, limited to the kidney. T2: Lesions have been divided into T2a and T2b. T2a is defined as tumor more than 7 cm but less than or equal to 10 cm in greatest dimension, limited to the kidney. T2b is defined as tumor greater than 10 cm, limited to the kidney. T3: Tumor extends into major veins or perinephric tissues, but not into the ipsilateral adrenal gland and not beyond Gerota's fascia. Lesions have been divided into T3a, T3b, and T3c. T3a: Tumor grossly extends into the renal vein or its segmental (muscle containing) branches, or tumor invades perirenal and/or renal sinus fat but not beyond Gerota's fascia. T3b: Tumor grossly extends into the vena cava below the diaphragm. T3c: Tumor grossly extends into the vena cava above the diaphragm or invades the wall of the vena cava. N0: No regional lymph node metastasis. N1: Metastasis in regional lymph node(s). M0: No distant metastasis. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D567C84B-4394-4E92-E053-4EBD850A2849","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D567C84B-43AD-4E92-E053-4EBD850A2849","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Kidney Cancer AJCC v7 Stage 2","valueDescription":"Kidney Cancer AJCC v7 Stage 2","ValueMeaning":{"publicId":"8003086","version":"1","preferredName":"Kidney Cancer AJCC v7 Stage 2","longName":"8003086","preferredDefinition":"Stage II includes: T2, N0, M0. T2: Lesions have been divided into T2a and T2b. T2a is defined as tumor more than 7 cm but less than or equal to 10 cm in greatest dimension, limited to the kidney. T2b is defined as tumor greater than 10 cm, limited to the kidney. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D567C84B-43B7-4E92-E053-4EBD850A2849","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D567C84B-43D0-4E92-E053-4EBD850A2849","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Kidney Cancer AJCC v7 Stage 1","valueDescription":"Kidney Cancer AJCC v7 Stage 1","ValueMeaning":{"publicId":"8003087","version":"1","preferredName":"Kidney Cancer AJCC v7 Stage 1","longName":"8003087","preferredDefinition":"Stage I includes: T1, N0, M0. T1: Lesions have been divided into T1a and T1b. T1a is defined as tumor 4 cm or less in greatest dimension, limited to the kidney. T1b is defined as tumor greater than 4 cm but not more than 7 cm in greatest dimension, limited to the kidney. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th Eds.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D567C84B-43DA-4E92-E053-4EBD850A2849","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D567C84B-43F3-4E92-E053-4EBD850A2849","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Thyroid Cancer AJCC v7 Stage 4","valueDescription":"Thyroid Cancer AJCC v7 Stage 4","ValueMeaning":{"publicId":"8003088","version":"1","preferredName":"Thyroid Cancer AJCC v7 Stage 4","longName":"8003088","preferredDefinition":"Thyroid Cancer AJCC v7 Stage 4","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D567C84B-43FD-4E92-E053-4EBD850A2849","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D567C84B-4416-4E92-E053-4EBD850A2849","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Thyroid Cancer AJCC v7 Stage 3","valueDescription":"Thyroid Cancer AJCC v7 Stage 3","ValueMeaning":{"publicId":"8003089","version":"1","preferredName":"Thyroid Cancer AJCC v7 Stage 3","longName":"8003089","preferredDefinition":"Thyroid Cancer AJCC v7 Stage 3","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D567C84B-4420-4E92-E053-4EBD850A2849","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D567C84B-4439-4E92-E053-4EBD850A2849","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Thyroid Cancer AJCC v7 Stage 2","valueDescription":"Thyroid Cancer AJCC v7 Stage 2","ValueMeaning":{"publicId":"8003090","version":"1","preferredName":"Thyroid Cancer AJCC v7 Stage 2","longName":"8003090","preferredDefinition":"Thyroid Cancer AJCC v7 Stage 2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D567C84B-4443-4E92-E053-4EBD850A2849","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D567C84B-445C-4E92-E053-4EBD850A2849","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Thyroid Cancer AJCC v7 Stage 1","valueDescription":"Thyroid Cancer AJCC v7 Stage 1","ValueMeaning":{"publicId":"8003091","version":"1","preferredName":"Thyroid Cancer AJCC v7 Stage 1","longName":"8003091","preferredDefinition":"Thyroid Cancer AJCC v7 Stage 1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D567C84B-4466-4E92-E053-4EBD850A2849","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D567C84B-447F-4E92-E053-4EBD850A2849","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Participant without Cancer Diagnosis","valueDescription":"Participant Without Cancer Diagnosis","ValueMeaning":{"publicId":"8002866","version":"1","preferredName":"Participant Without Cancer Diagnosis","longName":"8002866","preferredDefinition":"Someone who takes part in an activity.: Used to indicate the absence or lack of something or someone.: General term for detecting and classifying cancer in patients.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Participant","conceptCode":"C29867","definition":"Someone who takes part in an activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Without","conceptCode":"C25718","definition":"Used to indicate the absence or lack of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cancer Diagnosis","conceptCode":"C16213","definition":"General term for detecting and classifying cancer in patients.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D566D5E2-2207-2B60-E053-4EBD850AA29C","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D566D5E2-2220-2B60-E053-4EBD850AA29C","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Colorectal Cancer AJCC v7 Stage 4","valueDescription":"Colorectal Cancer AJCC v7 Stage 4","ValueMeaning":{"publicId":"8002874","version":"1","preferredName":"Colorectal Cancer AJCC v7 Stage 4","longName":"8002874","preferredDefinition":"Stage IV includes: IVA: (Any T, Any N, M1a); IVB: (Any T, Any N, M1b). M1a: Metastasis confined to one organ or site (e.g., liver, lung, ovary, nonregional node). M1b: Metastases in more than one organ/site or the peritoneum. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D567031C-948F-7D2B-E053-4EBD850AF3ED","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D567031C-94A8-7D2B-E053-4EBD850AF3ED","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Colorectal Cancer AJCC v7 Stage 3","valueDescription":"Colorectal Cancer AJCC v7 Stage 3","ValueMeaning":{"publicId":"8002875","version":"1","preferredName":"Colorectal Cancer AJCC v7 Stage 3","longName":"8002875","preferredDefinition":"Stage III includes: IIIA (T1-T2, N1/N1c, M0); (T1, N2a, M0); IIIB (T3-T4a, N1/N1c, M0); (T2-T3, N2a, M0); (T1-T2, N2b, M0); IIIC (T4a, N2a, M0); (T3-T4a, N2b, M0); (T4b, N1-N2, M0). T1: Tumor invades submucosa. T2: Tumor invades muscularis propria. T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor penetrates to the surface of the visceral peritoneum. T4b: Tumor directly invades or is adherent to other organs or structures. N0: No regional lymph node metastasis. N1: Metastasis in 1-3 regional lymph nodes. N1c: Tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional lymph node metastasis. N2: Metastasis in four or more regional lymph nodes. N2a: Metastasis in 4-6 regional lymph nodes. N2b: Metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D567031C-94B2-7D2B-E053-4EBD850AF3ED","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D567031C-94CB-7D2B-E053-4EBD850AF3ED","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Colorectal Cancer AJCC v7 Stage 2","valueDescription":"Colorectal Cancer AJCC v7 Stage 2","ValueMeaning":{"publicId":"8002876","version":"1","preferredName":"Colorectal Cancer AJCC v7 Stage 2","longName":"8002876","preferredDefinition":"Stage II includes: IIA (T3, N0, M0); IIB (T4a, N0, M0); IIC (T4b, N0, M0). T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor penetrates to the surface of the visceral peritoneum. T4b: Tumor directly invades or is adherent to other organs or structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D567031C-94D5-7D2B-E053-4EBD850AF3ED","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D567031C-94EE-7D2B-E053-4EBD850AF3ED","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Colorectal Cancer AJCC v7 Stage 1","valueDescription":"Colorectal Cancer AJCC v7 Stage 1","ValueMeaning":{"publicId":"8002877","version":"1","preferredName":"Colorectal Cancer AJCC v7 Stage 1","longName":"8002877","preferredDefinition":"Stage I includes: (T1, N0, M0); (T2, N0, M0). T1: Tumor invades submucosa. T2: Tumor invades muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D567031C-94F8-7D2B-E053-4EBD850AF3ED","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D567031C-9511-7D2B-E053-4EBD850AF3ED","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","deletedIndicator":"No"},{"value":"Ovary Cancer Unknown Stage","valueDescription":null,"ValueMeaning":{"publicId":"11028475","version":"1","preferredName":"Ovary Cancer Unknown Stage","longName":"11028475v1.00","preferredDefinition":"Ovary Cancer Unknown Stage","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5D6DF9E-09BE-5726-E053-731AD00A25FF","latestVersionIndicator":"Yes","beginDate":"2022-08-09","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2022-08-09","modifiedBy":"ZHWENDY","dateModified":"2022-08-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E5D6DF9E-09C2-5726-E053-731AD00A25FF","beginDate":"2022-08-09","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2022-08-09","modifiedBy":"ZHWENDY","dateModified":"2022-08-09","deletedIndicator":"No"},{"value":"Pancreas Cancer Unknown Stage","valueDescription":null,"ValueMeaning":{"publicId":"11028476","version":"1","preferredName":"Pancreas Cancer Unknown Stage","longName":"11028476v1.00","preferredDefinition":"Pancreas Cancer Unknown Stage","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5D6DF9E-09BF-5726-E053-731AD00A25FF","latestVersionIndicator":"Yes","beginDate":"2022-08-09","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2022-08-09","modifiedBy":"ZHWENDY","dateModified":"2022-08-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E5D6DF9E-09C3-5726-E053-731AD00A25FF","beginDate":"2022-08-09","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2022-08-09","modifiedBy":"ZHWENDY","dateModified":"2022-08-09","deletedIndicator":"No"},{"value":"Kidney Cancer Unknown Stage","valueDescription":null,"ValueMeaning":{"publicId":"11028477","version":"1","preferredName":"Kidney Cancer Unknown Stage","longName":"11028477v1.00","preferredDefinition":"Kidney Cancer Unknown Stage","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5D6DF9E-09C0-5726-E053-731AD00A25FF","latestVersionIndicator":"Yes","beginDate":"2022-08-09","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2022-08-09","modifiedBy":"ZHWENDY","dateModified":"2022-08-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E5D6DF9E-09C4-5726-E053-731AD00A25FF","beginDate":"2022-08-09","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2022-08-09","modifiedBy":"ZHWENDY","dateModified":"2022-08-09","deletedIndicator":"No"},{"value":"Melanoma Cancer Unknown Stage","valueDescription":null,"ValueMeaning":{"publicId":"11028478","version":"1","preferredName":"Melanoma Cancer Unknown Stage","longName":"11028478v1.00","preferredDefinition":"Melanoma Cancer Unknown Stage","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5D6DF9E-09C1-5726-E053-731AD00A25FF","latestVersionIndicator":"Yes","beginDate":"2022-08-09","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2022-08-09","modifiedBy":"ZHWENDY","dateModified":"2022-08-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E5D6DF9E-09C5-5726-E053-731AD00A25FF","beginDate":"2022-08-09","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2022-08-09","modifiedBy":"ZHWENDY","dateModified":"2022-08-09","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008528","version":"1","preferredName":"Protocol Administration","preferredDefinition":"the management of a research protocol and its case report forms.","longName":"PROT_ADM","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1ECAD41-A932-34B1-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"8003101","version":"1","preferredName":"Malignant Neoplasm Stage Assignment Name","preferredDefinition":"A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.:The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.:An allotting or an appointment to a particular person or use, or for a particular time or object.:The words or language units by which a thing is known.","longName":"C9305:C16899:C25426:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Assignment","conceptCode":"C25426","definition":"An allotting or an appointment to a particular person or use, or for a particular time or object.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D56826B2-DB9A-0EF8-E053-4EBD850A02BE","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ONEDATA","dateModified":"2022-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D566D5E2-21EC-2B60-E053-4EBD850AA29C","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"ZHWENDY","dateModified":"2022-08-09","changeDescription":"TL released; 2/24/22.; A212102/TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Slot Reservation Assignment","type":"Preferred Question Text","description":"Slot Reservation Assignment","url":null,"context":"Alliance"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5680087-A6F0-0A5B-E053-4EBD850AAB3D","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"TAYLORT","dateModified":"2022-02-24","changeDescription":"TL released; 2/24/22.; A212102/TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}